Athersys, Inc. (NASDAQ:ATHX) has received an average broker rating score of 0.00 () from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $9.00 for the company and are expecting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 150 out of 265 based on the ratings given to related companies.
Several brokerages have recently commented on ATHX. Maxim Group set a $9.00 price target on Athersys and gave the stock a “buy” rating in a research note on Saturday, March 11th. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Tuesday, March 14th. Finally, Needham & Company LLC began coverage on Athersys in a research note on Tuesday, February 7th. They set a “buy” rating and a $7.00 price target on the stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Web Breaking News and is owned by of Web Breaking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at http://www.webbreakingnews.com/2017/03/26/zacks-athersys-inc-athx-receives-consensus-recommendation-of-from-analysts.html.
Several large investors have recently made changes to their positions in the company. Oxford Asset Management purchased a new stake in shares of Athersys during the fourth quarter valued at approximately $105,000. NEXT Financial Group Inc raised its stake in shares of Athersys by 14.4% in the third quarter. NEXT Financial Group Inc now owns 106,100 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 13,350 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Athersys during the fourth quarter valued at approximately $617,000. State Street Corp raised its stake in shares of Athersys by 1.9% in the fourth quarter. State Street Corp now owns 1,119,590 shares of the biopharmaceutical company’s stock valued at $1,714,000 after buying an additional 20,680 shares during the period. Finally, Prudential PLC raised its stake in shares of Athersys by 8.9% in the fourth quarter. Prudential PLC now owns 2,150,000 shares of the biopharmaceutical company’s stock valued at $3,290,000 after buying an additional 175,000 shares during the period. 17.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of Athersys (NASDAQ:ATHX) opened at 1.14 on Tuesday. The firm’s market cap is $125.18 million. The firm’s 50-day moving average price is $1.17 and its 200 day moving average price is $1.59. Athersys has a 1-year low of $1.02 and a 1-year high of $2.69.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $0.45 million. Athersys had a negative return on equity of 22.82% and a negative net margin of 17.12%. Athersys’s revenue was down 90.7% compared to the same quarter last year. During the same period last year, the firm earned $0.04 EPS. On average, equities research analysts forecast that Athersys will post ($0.27) EPS for the current fiscal year.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.